Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Bret Gary Degraaff"'
Autor:
Alicia J. Morales, Edus H. Warren, Damian J. Green, Edward N. Libby, Pamela S. Becker, Bret Gary Degraaff, Timothy J. Martins, Rebecca Silbermann, Andrew J. Cowan, Niall Curley, Sylvia Chien, Jin Dai, Ted Gooley, David G. Coffey
Publikováno v:
JCO Precis Oncol
PURPOSE Multiple myeloma (MM) is a genetically heterogeneous malignancy characterized by variable treatment responses. Although numerous drugs have been approved in recent years, the ability to predict treatment response and tailor individual therapy
Autor:
Andrew J. Cowan, Pamela S. Becker, David G. Coffey, Cody Hammer, Edward N. Libby, Gabrielle A Zecha, Heather A. Smith, Jin Dai, Ted Gooley, Sylvia Chien, Kim Quach, Timothy S Martins, Josh Epworth, Bret Gary Degraaff
Publikováno v:
Blood. 134:1902-1902
Background: The treatment of multiple myeloma (MM) is optimized by use of combination regimens consisting of agents with different mechanisms of action. Panobinostat is a pan-inhibitor of histone deacetylases types I,II, and IV. Panobinostat, bortezo
Autor:
Pamela S. Becker, Sylvia Chien, Niall Curley, David G. Coffey, Edward N. Libby, Rebecca Silbermann, Edus H. Warren, Bret Gary Degraaff, Alicia J. Morales, Timothy S Martins, Damian J. Green, Andrew J. Cowan, Jin Dai, Ted Gooley
Publikováno v:
Blood. 134:1885-1885
Background: The response to treatment for patients with relapsed/refractory multiple myeloma (MM) is highly variable. This may in part be related to the broad genomic heterogeneity that has been reported across individual patients. We hypothesize tha